ArticleScientific reports2026
Experimental study on the influence of PDA-modified PDMS on the biological behavior of mouse fibroblasts.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Copper Integrated PDA-TA Nanocoating via One-Step Rapid Polymerization on Titanium for Anti-Thrombotic and Antibacterial Properties.Biomolecules · 2026Article
- Recent advances in sex-specific reproductive microphysiological systems for the systematic evaluation of assisted reproductive technology.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Polydimethylsiloxane (PDMS) is widely used across various fields due to its biocompatibility and chemical inertness. However, its surface hydrophobicity limits its application in cell culture. This study modifies PDMS surfaces with polydopamine (PDA) to mitigate hydrophobicity, with a primary focus on evaluating fibroblast biocompatibility on the modified substrate at a selected concentration (0.2%) and exploring its potential for wound healing applications. PDMS was surface-modified with PDA solutions at concentrations of 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, and 0.5% (W/V%) to evaluate its wettability. Based on the preliminary screening of material contact angle and cell viability after material-cell interaction, 0.2% PDA-PDMS was chosen for all subsequent biological tests. Mouse fibroblasts L929 were cultured on the selected substrate. Cell proliferation was determined by the CCK-8 assay. FITC/DAPI fluorescent staining, scratch assay, and RT-qPCR were used to evaluate cell spreading, migration, and gene expression. Statistical analysis employed t-test, one-way ANOVA, and two-way ANOVA. All PDA concentrations significantly reduced material contact angles (P < 0.01). At 48 h of interaction, the 0.2% PDA-PDMS exhibited the highest cell viability in CCK-8 assay among all concentrations (P < 0.0001), with significantly increased cell viability observed at 48 and 72 h (P < 0.05). The cell scratch assay showed that L929 cultured on 0.2% PDA-PDMS had largely recovered by 36 h post-scratch, with no significant difference compared to cells cultured on PDA-PDMS from 0 h to 18 h (P > 0.05). RT-qPCR indicated significantly elevated expression of transforming growth factor-β1 (TGF-β1) and collagen α-1 (III) chain (COL3A1) at 24 h and 36 h, and α-smooth muscle actin (α-SMA) at 48 h, compared to control (P < 0.05). PDA significantly decreased the hydrophobicity of the PDMS and enhanced its wettability. Based on preliminary assessment across concentrations, 0.2% PDA-PDMS demonstrated the highest cell proliferation and viability among the tested groups. PDA surface modification at this concentration also enhanced cell migration ability, improved cell morphology and spreading, and increased the expression of related genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.